News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C’s Life Sciences Practice Represents Boston Biomedical in its Agreement with Dainippon Sumitomo Pharma Co., Ltd. to be Acquired for up to $2.63 Billion



3/5/2012 6:04:27 AM

BOSTON--(BUSINESS WIRE)--The Life Sciences Practice of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented its client, Boston Biomedical, Inc. (BBI), in the company’s definitive agreement to be acquired by Dainippon Sumitomo Pharma Co., Ltd. (DSP). Under the terms of the agreement, DSP will acquire BBI for up to $2.63 billion in total, which includes $200 million upfront, up to $540 million in development milestone payments, and up to $1.89 billion in sales milestone payments.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES